Choose your location
Select your country or region to view content specific to your country.
Product News You can check out the latest product information
-
Launched Magicplex™ CT/NG Real-Time Detection
Launched Magicplex™ CT/NG Real-Time Detection
Feb 03, 2010｜ Magicplex CT/NG Real-Time Detection
-
Launched Magicplex™ STI 1 Amplification
Magicplex™ STI 1 Amplification Detection of 5 most common STI pathogens STI 1 Real-time Test, using READ™, amplifies the 5 most common pathogens that cause sexually transmitted inflammations in order to conduct the simultaneous tests by panels (Panel 1 (Chlamydia trachomatis, Neisseria gonorrhoeae) and Panel 2 (Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum)). C. trachomatis, N. gonorrhoeae, M. genitalium, M. hominis and U. urealyticum are the common causes of sexually-transmitted infections. Despite their high frequencies, most of cases are asymptomatic, which cause the delay of infection’s treatment and its eventual development into PID, ectopic pregnancy, infertility, chronic pelvic pain, cervicitis and urethritis. Magicplex™ STI 1 Real-time Test demonstrates a higher accuracy than the conventional diagnostic methods (e.g. Culture, Immuno assay, Conventional PCR, Real-time PCR) with reduction in test duration and additional test costs by Multiplex. It will be the perfect tool for preventing the spread of sexually transmitted diseases with rapid and accurate diagnosis.
Feb 02, 2010｜ Magicplex STI 1 Amplification
-
Launched Anyplex™ VanR Real-Time detection
Anyplex™ VanR Real-Time detection Simultaneous detection of vanA, vanB, and vanC geneEnterococci are the major cause of surgical-site infections and the third leading cause of urinary tract and bloodstream infections. Vancomycin is an antibiotic that is often used to treat infections caused by these Enterococci. In some instances, Enterococci become resistant to this drug and thus are called vancomycin-resistant Enterococci (VRE). Most VRE infections occur in hospitals. Vancomycin-resistant Enterococci (VRE) are now an increasingly important problem in hospitals worldwide. Both vanA and vanB genes are transferable and can spread from organism to organism. For this reason, an accurate detection is necessary in order to separate the carriers from patients. On the other hand, vanC genes are not transferable and less significant clinically, and moreover they do not require carriers to be secluded. However, the detection of vanC is still important for discrimination of VRE with acquired resistance as well as for preventing unnecessary procedures for infection management.
Feb 01, 2010｜ Anyplex™ VanR Real-time Detection
-
Launched Anyplex™ MTB/NTM Real-Time Detection
Anyplex™ MTB/NTM Real-Time Detection Identification of MTB dissociated from NTM Anyplex™ MTB/NTM Real-time Detection is designed for identification of Mycobacterium tuberculosis (MTB) dissociated from non-tuberculosis mycobacteria (NTM) in various specimens such as sputum, aseptic fluids (pleural fluid, blood, bone marrow aspiration), bronchial washing, fresh tissue, culture specimens (solid and liquid culture), urine and stool. Although culture is a standard method to diagnose active tuberculosis, it is difficult to discriminate MTB from NTM by culture due to their similar colony morphologies. Anyplex™ MTB/NTM Real-time Detection is a DNA-based testing product which can accurately discriminate MTB from NTM. Therefore, this product enables a proper treatment of the patients by determining MTB from NTM infection.
Jan 02, 2010｜ Anyplex™ MTB/NTM Real-time Detection
-
Obtained CE-IVD marking for Seeplex® CT ACE Detection
Seeplex® CT ACE Detection Seegene's Seeplex® CT ACE Detction has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.
Jan 01, 2010｜ Seeplex® CT ACE Detection
-
Launched Magicplex™ VanR Real-Time Detection
Magicplex™ VanR Real-Time Detection Simultaneous detection of vanA, vanB, and vanC genes The importance of testing for VRE VRE (vancomycin-resistant enterococci) are an important category of opportunistic pathogenic bacteria, the occurrence of which has risen in frequency worldwide with the increase in the use of vancomycin. As most VRE display resistance to multiple drugs, they are difficult to treat. In addition, their resistant characteristics may be passed on to other opportunistic pathogenic bacteria, such as the Staphylococcus aureus, which can be highly problematic. Therefore, in order to prevent the spread of VRE in the hospital, conducting a test for VRE quickly and accurately is essential. Vancomycin resistance genotyping vanA and vanB genes are transferable and can spread from organism to organism. So, accurate detection is required in order to separate the carriers from patients. vanC genes are not transferable and have little clinical importance, and do not require the carrier to be secluded. The detection of vanC is necessary for discriminating VRE with acquired resistance, and for preventing unnecessary infection management procedures. VRE diagnostic methods Disk diffusion test and automated systems, such as the Vitek system or the Microscan, have high accuracy and reliability. These methods, however, are able to only test for phenotypes, and cannot determine the exact genotypes. Moreover, as there have been reports of VRE which has incongruent genotypes against its phenotypes, a molecular biological test is necessary in order to identify resistant genotypes.
Jan 01, 2010｜ Magicplex VanR Real-Time Detection
-
Obtained CE-IVD marking for Allplex™ Bacterial Vaginosis Assay
Allplex™ Bacterial Vaginosis Assay simultaneously detects 7 bacteria (G. vaginalis, A. vaginae, Megasphaera type 1, BV-associated bacteria 2, Mobiluncus spp., B. fragilis, Lactobacillus spp.) associated with vaginosis. It provides quantitative information of 3 major bacteria (G. vaginalis, A. vaginae, Lactobacillus spp.). Based on Seegene’s proprietary MuDT™ technology, this assay makes it possible to report individual Ct value of multiple bacteria in a single channel. The CE-IVD mark will allow more opportunities for Seegene to market and sell within the European Union.
Dec 15, 2009｜ Allplex™ Bacterial Vaginosis Assay
-
Obtained Medical Device License By Health Canada : Seeplex® Diarrhea-V ACE Detection
Seeplex® Diarrhea-V ACE Detection Detection of diarrhea-causing viruses and bacteria Obtained Medical Device License By Health Canada : Seeplex® Diarrhea-V ACE Detection
Dec 01, 2009｜ Seeplex® Diarrhea-V ACE Detection